How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

248 results for

Tinea Corporis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

2. Topical antifungal treatments for tinea cruris and tinea corporis. (PubMed)

Topical antifungal treatments for tinea cruris and tinea corporis. Tinea infections are fungal infections of the skin caused by dermatophytes. It is estimated that 10% to 20% of the world population is affected by fungal skin infections. Sites of infection vary according to geographical location, the organism involved, and environmental and cultural differences. Both tinea corporis, also referred to as 'ringworm' and tinea cruris or 'jock itch' are conditions frequently seen by primary care (...) ), MEDLINE (from 1946), EMBASE (from 1974), and LILACS (from 1982). We also searched five trials registers, and checked the reference lists of included and excluded studies for further references to relevant randomised controlled trials. We handsearched the journal Mycoses from 1957 to 1990.Randomised controlled trials in people with proven dermatophyte infection of the body (tinea corporis) or groin (tinea cruris).Two review authors independently carried out study selection, data extraction, assessment

Full Text available with Trip Pro

2014 Cochrane

3. Tinea Corporis Infection - Guidelines for Prescribing Topical Antifungals

Tinea Corporis Infection - Guidelines for Prescribing Topical Antifungals Tinea Corporis Infection - Guidelines for Prescribing Topical Antifungals - medSask Home - College of Pharmacy and Nutrition - University of Saskatchewan Toggle Menu Search the U of S Search Tinea Corporis Infection - Guidelines for Prescribing Topical Antifungals Fungal or tinea infections of the skin are common, with tinea corporis (ringworm) and tinea cruris (jock itch) affecting 10 to 20% of the general population (...) at some point in their lifetime and up to 44% of wrestlers (known as tinea corporis gladiatorum) Men are more often affected than women Superficial fungal infections of the skin are caused by three dermatophytes; Trichophyton, Epidermophyton and Microsporum which use the keratin layer of the epidermis as their source of nutrition Tinea infection is classified by location on the body, not by the causative organism Tinea infections are contagious and are spread by skin-to-skin contact with infected

2017 medSask

4. Unusual Presentation of Tinea Corporis Associated With the Use of a Microneedling Device (PubMed)

Unusual Presentation of Tinea Corporis Associated With the Use of a Microneedling Device 29025223 2018 10 24 2018 12 02 1527-330X 37 7 2017 07 01 Aesthetic surgery journal Aesthet Surg J Unusual Presentation of Tinea Corporis Associated With the Use of a Microneedling Device. NP69-NP72 10.1093/asj/sjx086 da Cunha Nélia Margarida Martins NMM Dermatology Department, Hospital de Santo António dos Capuchos-Centro Hospitalar de Lisboa Central, Lisboa, Portugal. Campos Sara Leite de Azevedo SLA (...) Naphthalenes therapeutic use Needles adverse effects Rejuvenation Skin microbiology pathology Skin Aging Terbinafine Tinea diagnosis drug therapy etiology transmission 2017 10 14 6 0 2017 10 14 6 0 2018 10 26 6 0 ppublish 29025223 3868434 10.1093/asj/sjx086 PMC5846698 J Am Acad Dermatol. 2016 Feb;74(2):348-55 26549251 JAMA Dermatol. 2014 Jan;150(1):68-72 24258303 Indian Dermatol Online J. 2016 Jul-Aug;7(4):244-54 27559496 Aesthet Surg J. 2017 Jan;37(1):71-83 27530764 Aesthet Surg J. 2016 Apr;36(4):NP168-70

Full Text available with Trip Pro

2017 Aesthetic surgery journal

5. Analysis on curative effects and safety of 2% liranaftate ointment in treating tinea pedis and tinea corporis & cruris. (PubMed)

Analysis on curative effects and safety of 2% liranaftate ointment in treating tinea pedis and tinea corporis & cruris. The paper is intended to analyze and evaluate the specific curative effect and safety of 2% liranaftate ointment in treating patients with tinea pedis and tinea cruris. 1,100 cases of patients with tinea pedis and tinea corporis & cruris were selected as research objects and were divided into two groups according to the random number table method. They were treated (...) with different methods: 550 cases of patients were treated with 2% liranaftate ointment for external use in the observation group and the rest 550 cases of patients were treated with 1% bifonazole cream in the control group. The treatment time was two weeks for patients with tinea corporis & cruris and four weeks for those with tinea pedis respectively. Meanwhile, the one-month follow-up visit was conducted among the patients to compare the curative effects of two groups. After the medication, the curative

2017 Pakistan journal of pharmaceutical sciences

6. Tinea corporis in a wrestling team cheerleader (PubMed)

Tinea corporis in a wrestling team cheerleader 28492027 2019 02 26 2352-6475 2 4 2016 Dec International journal of women's dermatology Int J Womens Dermatol Tinea corporis in a wrestling team cheerleader. 143-144 10.1016/j.ijwd.2016.10.001 McClanahan C C Department of Dermatology, University of Iowa. Wanat K K Department of Dermatology, University of Iowa. eng Case Reports 2016 12 06 Netherlands Int J Womens Dermatol 101654170 2352-6475 athlete cheerleader skin infection tinea tinea gladiatorum

Full Text available with Trip Pro

2016 International journal of women's dermatology

7. Correlation of invitro susceptibility based on MICs and <i>SQLE</i> mutations with clinical response to terbinafine in patients with tinea corporis/cruris. (PubMed)

Correlation of invitro susceptibility based on MICs and SQLE mutations with clinical response to terbinafine in patients with tinea corporis/cruris. Recalcitrant dermatophytoses are on the rise in India. High MICs of terbinafine (TRB) and squalene epoxidase (SQLE) gene mutations conferring resistance in Trichophyton spp. have been recently documented. However, studies correlating laboratory data with clinical response to TRB in tinea corporis/cruris are lacking. For this study, we (...) investigated the clinicomycological profile of 85 tinea corporis/cruris patients and performed antifungal susceptibility testing by CLSI microbroth dilution and SQLE mutation analysis of the isolates obtained and correlated these with the responses to TRB. Patients confirmed by potassium hydroxide (KOH) mounting of skin scrapings were started on TRB at 250 mg once a day (OD). If >50% clinical clearance was achieved by 3 weeks, the same dose was continued (group 1). If response was <50%, the dose

2018 Antimicrobial Agents and Chemotherapy

8. The association of isoconazole - diflucortolone in the treatment of paediatric tinea corporis. (PubMed)

The association of isoconazole - diflucortolone in the treatment of paediatric tinea corporis. Tinea corporis is a common mycotic infection in children. Staphylococcus aureus superinfections may be observed in atopic children with tinea corporis suffering from severe pruritus and consequent scratching.From 2006 to 2011, we observed 288 children with mycologically proven tinea corporis. In 39 of them (13.5%) tinea corporis was superinfected by S. aureus: all these children were affected (...) by atopic dermatitis. We interpreted these bacterial superinfections as the clinical result of scratching due to pruritus.In 2012, we decided to treat all children with a single lesion of tinea corporis with a combination of 1% isoconazole nitrate and 0.1% diflucortolone valerate cream (one application/day for 5-7 days), followed by a treatment with isoconazole or clotrimazole or ciclopirox cream (two applications/day for two weeks).From 2012 to 2014, we observed 108 children with tinea corporis

2017 Journal of Dermatological Treatment

9. Porokeratosis Ptychotropica Coexisting with Tinea Corporis (PubMed)

Porokeratosis Ptychotropica Coexisting with Tinea Corporis 28761308 2018 11 13 1013-9087 29 4 2017 Aug Annals of dermatology Ann Dermatol Porokeratosis Ptychotropica Coexisting with Tinea Corporis. 506-508 10.5021/ad.2017.29.4.506 Lee Solam S Department of Dermatology, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Korea. Choe Sung Jay SJ Department of Dermatology, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju

Full Text available with Trip Pro

2017 Annals of dermatology

10. Tinea corporis in a child caused by Arthroderma benhamiae (PubMed)

Tinea corporis in a child caused by Arthroderma benhamiae 27747922 2018 01 12 2018 11 13 1365-2230 41 8 2016 Dec Clinical and experimental dermatology Clin. Exp. Dermatol. Tinea corporis caused by Arthroderma benhamiae in a child. 955-957 10.1111/ced.12966 El-Heis S S Department of Dermatology and MRC Lifecourse Epidemiology Unit (University of Southampton), University Hospital Southampton NHS Foundation Trust, Southampton, UK. Borman A M AM Public Health England National, Bristol, UK. Szekely (...) Dermatol 7606847 0307-6938 IM Arthrodermataceae isolation & purification Child, Preschool Dermatomycoses microbiology Female Humans Tinea microbiology No conflict of interest 2016 04 15 2016 10 18 6 0 2018 1 13 6 0 2016 10 18 6 0 ppublish 27747922 10.1111/ced.12966 PMC5248975 EMS71114 J Dtsch Dermatol Ges. 2014 Sep;12(9):749-77 25176455 J Dermatol Sci. 2001 Sep;27(1):14-20 11457639 Vet Dermatol. 2009 Feb;20(1):13-8 18699813 Mycopathologia. 2010 Jun;169(6):445-9 20165922 Mycoses. 2010 Nov;53(6):530-2

Full Text available with Trip Pro

2016 Clinical and experimental dermatology

11. Safety and Efficacy of Product 33525 in Pediatric Subjects With Tinea Corporis

Safety and Efficacy of Product 33525 in Pediatric Subjects With Tinea Corporis Safety and Efficacy of Product 33525 in Pediatric Subjects With Tinea Corporis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Safety and Efficacy of Product 33525 in Pediatric Subjects With Tinea Corporis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02767947 Recruitment Status : Completed First Posted : May 11, 2016 Last Update Posted : December 15, 2017 Sponsor: Valeant Pharmaceuticals International, Inc. Information

2016 Clinical Trials

12. Efficacy and Safety of Naftifine HCl Cream 2% in the Treatment of Pediatric Subjects With Tinea Corporis. (PubMed)

Efficacy and Safety of Naftifine HCl Cream 2% in the Treatment of Pediatric Subjects With Tinea Corporis. Tinea corporis is fungal infection of body surfaces other than the feet, groin, scalp, or beard. Naftifine hydrochloride is a topical antifungal of the allylamine class used to treat tinea corporis, displaying fungicidal activity and clinically significant anti-bacterial and anti-inflammatory effects.
To evaluate the efficacy and safety of two-weeks once daily application of naftifine (...) cream 2% in the treatment of tinea corporis among pediatric subjects.
At baseline, 231 subjects were randomly assigned 1:1 to naftifine cream 2% (n=116) and vehicle (n=115). Treatment effect consisting of mycologic determination (KOH and dermatophyte cultures) and scoring of clinical symptom severity was evaluated at baseline, week 2 (end of treatment) and week 3. Efficacy was analyzed in 181 subjects (n=88, naftifine; n=93, vehicle) with a positive baseline dermatophyte culture and KOH for whom

2016 Journal of drugs in dermatology : JDD

13. Tinea Corporis Gladiatorum

Tinea Corporis Gladiatorum Tinea Corporis Gladiatorum Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Tinea Corporis Gladiatorum Tinea (...) Corporis Gladiatorum Aka: Tinea Corporis Gladiatorum From Related Chapters II. Definition variant seen in wrestlers III. Epidemiology Seen in wrestlers from skin-to-skin contact IV. Signs Characteristics Classic s as described above or Erythematous s or s Distribution Head, neck and arms V. Management See VI. Prevention Lesions must be completely and securely covered for wrestlers to participate Wrestlers with extensive involvement may return to sport after one week of treatment VII. References Images

2018 FP Notebook

14. Tinea Corporis

Tinea Corporis Tinea Corporis Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Tinea Corporis Tinea Corporis Aka: Tinea Corporis (...) cases due to hepatotoxicity If is used, requires s at baseline and again weekly X. Complications Deep follicular (Majocchi's Granuloma) Complication of use More commonly affects women, and most often on legs XI. References Gilbert (1999) Sanford Guide to Antimicrobials Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Tinea Corporis." Click on the image (or right click) to open the source website in a new browser window. Related

2018 FP Notebook

15. Luzu (luliconozole) - For the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum, in patients 18 years of age and older

Luzu (luliconozole) - For the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum, in patients 18 years of age and older Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - LUZU (luliconazole) Cream Company: Medicis Pharmaceutical Corporation Application No.: 204153 Approval Date: 11/14/2013 Persons

2013 FDA - Drug Approval Package

16. Evidence-based topical treatments for tinea cruris and tinea corporis: a summary of a Cochrane systematic review. (PubMed)

Evidence-based topical treatments for tinea cruris and tinea corporis: a summary of a Cochrane systematic review. Tinea cruris and tinea corporis are common fungal infections. Most can be treated with a variety of topical antifungals. This review aimed to assess the evidence for the effectiveness and safety of topical treatments for tinea cruris and tinea corporis. Searches included the Cochrane Skin Group Specialised Register, CENTRAL in The Cochrane Library, Medline, Embase, LILACS

2015 British Journal of Dermatology

17. Efficacy and safety of terbinafine hydrochloride 1% cream vs eberconazole nitrate 1% cream in localised tinea corporis and tinea cruris. (PubMed)

Efficacy and safety of terbinafine hydrochloride 1% cream vs eberconazole nitrate 1% cream in localised tinea corporis and tinea cruris. To study and compare the efficacy and safety of topical terbinafine hydrochloride 1% cream and eberconazole nitrate 1% cream in localized tinea corporis and cruris.Patients were randomized after considering various inclusion and exclusion criteria into two groups. Group A (treated with terbinafine 1% cream for 3 weeks) and group B (treated with eberconazole 1

Full Text available with Trip Pro

2014 Indian dermatology online journal

18. Tinea Cruris Skin Infection - Guidelines for Prescribing Topical Antifungals

Tinea Cruris Skin Infection - Guidelines for Prescribing Topical Antifungals Tinea Cruris Skin Infection - Guidelines for Prescribing Topical Antifungals - medSask Home - College of Pharmacy and Nutrition - University of Saskatchewan Toggle Menu Search the U of S Search Tinea Cruris Skin Infection - Guidelines for Prescribing Topical Antifungals Fungal or tinea infections of the skin are common, with tinea corporis (ringworm) and tinea cruris (jock itch) affecting 10 to 20% of the general (...) . Available at by subscription. (In Saskatchewan available through .) Tinea corporis . In: DynaMed. Available at by subscription. (In Saskatchewan available through . Goldstein A, Goldstein B. Dermatophyte (tinea) infections. In: UpToDate . Available at by subscription. In : C-Health. . (Free access) In: Mayo Clinic. . (Free access ) Ringworm or tinea . In Bluebook – Guidelines for the control of infectious diseases (Free access) Prepared by medSask, Your Medication Information Service Reviewed by Dr. P

2017 medSask

19. Tinea Pedis Infection - Guidelines for Prescribing Topical Antifungals

dermatophytes proliferate in warm and humid places such as showers, swimming pools and changing rooms Athlete’s foot occurs most commonly between the toes and may spread to the instep or sole. The skin may be cracked or scaly with blisters, inflammation and an itching or burning sensation. It may also cover the soles of the feet and involve the toenails. This is called moccasin-type infection Tinea pedis is often the cause of tinea cruris or corporis from self-inoculation (touching affected feet to other (...) of human lactation 2001;17:160-6 Miller P. Dermatological Conditions: Fungal Skin Infections. CTMA. In: RxTx [Internet]. Canadian Pharmacists Association. Available from: . (In Saskatchewan available through .) Mallen A. Athlete’s foot. CTMA. In: RxTx [Internet]. Canadian Pharmacists Association. Available from: . (In Saskatchewan available through .) Stone S. Antifungal treatment chart. In: RxFiles. Available at by subscription. (In Saskatchewan available through .) Tinea corporis . In: DynaMed

2017 medSask

20. A Randomized Study Evaluating the Safety and Efficacy of Luliconazole Cream in Pediatric Subjects With Tinea Corporis

A Randomized Study Evaluating the Safety and Efficacy of Luliconazole Cream in Pediatric Subjects With Tinea Corporis Safety and Efficacy of Product 33525 in Pediatric Subjects With Tinea Corporis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove (...) one or more studies before adding more. Safety and Efficacy of Product 33525 in Pediatric Subjects With Tinea Corporis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02767947 Recruitment Status : Completed First Posted : May 11, 2016 Last Update Posted : December 15, 2017 Sponsor: Valeant

2015 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>